Medium-horizon Alzheimer's disease progression prediction is difficult because future clinical scores can remain tied to baseline severity, while biomarker histories are irregular and incompletely observed. We develop an anchor-based analysis of 24-month Clinical Dementia Rating Sum of Boxes (CDR-SB) change using harmonized Alzheimer's Disease Neuroimaging Initiative (ADNI) tables. Each labeled sample is anchored at a mild cognitive impairment visit, uses only clinical and biomarker history observed at or before that anchor, and defines the response as CDR-SB at the future visit closest to 24 months within an 18--30 month window minus anchor CDR-SB. The analytic cohort contains 2,600 labeled anchors from 858 participants and 7,276 longitudinal rows. We propose a residual gap-aware transformer that combines a mixed-effects statistical reference with transformer-based residual learning from pre-anchor clinical and biomarker histories. The model uses participant-level random intercepts in the mixed-effects reference, observation-level triplet tokenization for irregular histories, and a learned nonnegative time-gap penalty inside self-attention. We compare the proposed model with a Bayesian-information-criterion-selected linear mixed-effects baseline, GRU-D, and STraTS under repeated participant-level train--test splits. Across five participant-level random seeds, the proposed model achieves the best mean test performance across all reported metrics, reducing MSE by 13.1% and increasing prediction--observation correlation by 26.4% relative to the mixed-effects baseline. It also improves over both GRU-D and STraTS in mean error and correlation. These results show that statistical anchoring and gap-aware residual learning provide a useful structure for medium-horizon Alzheimer's disease progression prediction.

Acquisition differences across sites, scanners, and protocols in dMRI introduce variability that complicates structural connectome analysis. This motivates deep learning models that can represent high-dimensional connectomes in a low-dimensional space while explicitly separating acquisition-related effects from biological variation. Conventional dimensionality reduction methods model all variance as continuous, so acquisition effects often get absorbed into a continuous latent space. Recent hybrid latent-space models combine discrete and continuous components to address this, but typically require manual capacity tuning to ensure the discrete component captures the intended variability. We introduce an unsupervised framework that removes this manual tuning by architecturally annealing encoder outputs before decoding, allowing the model to adaptively balance discrete and continuous latent variables during training. To evaluate it, we curated a dataset of N=7,416 structural connectomes derived from dMRI, spanning ages 2 to 102 and 13 studies with 25 unique acquisition-parameter combinations. Of these, 5,900 are cognitively unimpaired, 877 have mild cognitive impairment (MCI), and 639 have Alzheimer's disease (AD). We compare against a standard VAE, PCA with k-means clustering, and hybrid models that anneal only through the loss function. Our architectural annealing produces stronger site learning (ARI=0.53, p<0.05) than these baselines. Results show that a hybrid continuous-discrete latent space, with architectural rather than loss-based annealing, provides a useful unsupervised mechanism for capturing acquisition variability in dMRI: by jointly modeling smooth and categorical structure, the Joint-VAE recovers clusters aligned with scanner and protocol differences.

Testing for'Bad Cholesterol' Doesn't Tell the Whole Story So why don't more doctors use it? For decades, assessing cholesterol risk has been built around a simple idea: Lower "bad" cholesterol, lower your chance of a heart attack . The test at the center of that approach measures how much low-density lipoprotein, or LDL cholesterol, is circulating in part of the blood. It has shaped everything from clinical guidelines to the widespread use of statins, medications that reduce LDL. Lowering LDL cholesterol reduces heart attacks, strokes, and early death.

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon. US-based pharmaceutical company Moderna confirmed that it has been working on the development of hantavirus vaccines in collaboration with the Vaccine Innovation Center of Korea University College of Medicine (VIC-K). This comes after an outbreak of hantavirus occurred on a Dutch cruise ship that sailed from Argentina and disembarked its passengers and crew in the Canary Islands on May 10. At least three people aboard the MV died, and several cases were reported as serious.

Jeffrey Epstein scrawled suicide note finally released: 'No fun. Surprising fate of CNN founder Ted Turner's multibillion-dollar fortune after thrice-married father-of-five died aged 87 Wall Street Titan lays out his ultimate revenge for woke NYC mayor Mamdani's'creepy weird' video Mike Vrabel'rented a boat with pregnant Dianna Russini in 2021' months before she welcomed first son Ultimate Spirit Airlines compensation guide: 'Magic words' to tell your bank for BIGGEST refund... what to do if you DIDN'T use a credit card... how to reclaim higher cost of new flights.... and'rescue' option when all else fails Once-bustling Nevada vacation resort becomes America's newest GHOST TOWN as its final hotel closes Farrah Fawcett's twisted family secrets: Siblings of her devil-horned son accused of hideous knife spree reveal dark childhood home truths Tragic Saved By The Bell star Dustin Diamond's residual pay revealed after his shock death at age 44 Rat virus'was brought onto cruise ship by birdwatcher couple who visited garbage dump to snap birds before setting off': Possible cause revealed - as Brits face eight-week quarantine Scandal as female World Cup soccer player is accused by police of raping baby-faced boy, 14, up to'three times a week' Triple Crown thrown into disarray with major announcement from Kentucky Derby winner Golden Tempo's trainer The photos that say it all! Justin Baldoni beams as he steps out with his wife for the first time since Blake Lively's humiliating lawsuit settlement The next generation of Ozempic is here. Turbo shots deliver 250% more weight loss... at record speeds. Patients are begging for them - but there's a major warning: DR SHEILA NAZARIAN Meghan Markle shares unseen photo of Prince Archie asleep on Harry's chest as a baby to celebrate his 7th birthday I sat with FedEx child killer Tanner Horner for weeks.

Regularization is often used in high-dimensional regression settings to generate a sparse model, which can save tremendous computing resources and identify predictors that are most strongly associated with the response. When the predictors can be represented by a Gaussian graphical model, the structure of the predictor graph can be exploited during regularization. Our proposed model exploits this underlying predictor graph structure by decomposing the estimated coefficient vector into a sum of latent variables that correspond to the sum of each node contribution to the coefficient vector. Regularization is then performed on the latent variables rather than on the coefficient vector directly. We use a penalty function that permits a clear user-defined trade-off between the L1 and L2 penalties and propose a novel proximal projection during optimization. Further, our implementation computes the projection operator for the intersection of selected groups, which conserves more computing resources compared to predictor duplication methods, especially for high-dimensional data. Through simulation, we evaluate the performance of our approach under different graph structures and node counts, and present results on real-world data. Results suggest that our method exhibits stable performance relative to other singly or doubly sparse graphical regression models.

The Next Alzheimer's Breakthrough Will Take More Than Just Science At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes--and next steps--of where treatment is headed next. Alzheimer's research is entering a new phase, as treatments that have taken decades to develop begin to reach patients . But getting those advances to people will depend on more than scientific progress alone, according to pioneering Alzheimer's researcher John Hardy . Speaking at WIRED Health in April, Hardy, chair of the Molecular Biology of Neurological Disease at University College London, said that alongside more effective drugs, better diagnosis and political will were still needed to improve treatment of Alzheimer's disease. "We've got to get better," he said.

We study high-dimensional mediation analysis in which exposures, mediators, and outcomes are all multivariate, and both exposures and mediators may be high-dimensional. We formalize this as a many (exposures)-to-many (mediators)-to-many (outcomes) (MMM) mediation analysis problem. Methodologically, MMM mediation analysis simultaneously performs variable selection for high-dimensional exposures and mediators, estimates the indirect effect matrix (i.e., the coefficient matrices linking exposure-to-mediator and mediator-to-outcome pathways), and enables prediction of multivariate outcomes. Theoretically, we show that the estimated indirect effect matrices are consistent and element-wise asymptotically normal, and we derive error bounds for the estimators. To evaluate the efficacy of the MMM mediation framework, we first investigate its finite-sample performance, including convergence properties, the behavior of the asymptotic approximations, and robustness to noise, via simulation studies. We then apply MMM mediation analysis to data from the Alzheimer's Disease Neuroimaging Initiative to study how cortical thickness of 202 brain regions may mediate the effects of 688 genome-wide significant single nucleotide polymorphisms (SNPs) (selected from approximately 1.5 million SNPs) on eleven cognitive-behavioral and diagnostic outcomes. The MMM mediation framework identifies biologically interpretable, many-to-many-to-many genetic-neural-cognitive pathways and improves downstream out-of-sample classification and prediction performance. Taken together, our results demonstrate the potential of MMM mediation analysis and highlight the value of statistical methodology for investigating complex, high-dimensional multi-layer pathways in science. The MMM package is available at https://github.com/THELabTop/MMM-Mediation.

Collecting multiple types of data on the same set of subjects is common in modern scientific applications including, genomics, metabolomics, and neuroimaging. Joint and Individual Variance Explained (JIVE) seeks a low-rank approximation of the joint variation between two or more sets of features captured on common subjects and isolates this variation from that unique to eachset of features. We develop an expectation-maximization (EM) algorithm to estimate a probabilistic model for the JIVE framework. The model extends probabilistic principal components analysis to multiple data sets. Our maximum likelihood approach simultaneously estimates joint and individual components, which can lead to greater accuracy compared to other methods. We apply ProJIVE to measures of brain morphometry and cognition in Alzheimer's disease. ProJIVE learns biologically meaningful courses of variation, and the joint morphometry and cognition subject scores are strongly related to more expensive existing biomarkers. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Code to reproduce the analysis is available on our GitHub page.